DSP: Phase 1/2 DSP-5336 in Acute Leukemia

Purpose of this Study

We are doing this study to find out how well an experimental drug called DSP-5336 (the study drug) works in people with AML or ALL.

Who Can Participate?

Eligibility

Adults ages 18+ who:<ul>
<li>Are diagnosed with Relapsed or Refractory AML or ALL</li>
<li>Have a confirmed KMT2A (MLL)-fusion or NPM1 mutation</li>
<li>Have acceptable organ function</li></ul>
For more information about who can join this study, please contact the study team at 919-660-2077.

What is Involved?

If you choose to join this study, you will go through a screening period to find out if you are eligible. During this screening period, you will:<ul>
<li>Have a physical exam</li>
<li>Have a heart scan (ECG)</li>
<li>Have blood draws</li></ul>
After the screening period, this study is divided into 2 parts. In Part 1, you will be assigned to either:<ul>
<li>Arm A (not taking a type of antifungal treatment); OR</li>
<li>Arm B (you are taking a type of antifungal treatment)</li></ul>
In Part 2, you will be assigned to either:<ul>
<li>Arm A [R/R AML with Mixed Lineage Leukemia that is rearranged (MLLr AML)]; OR</li>
<li>Arm B [R/R leukemia that has the Nucleophosmin 1 gene mutated (NPM1)]</li></ul>
The study drug will be taken by mouth twice daily.

Once you stop taking the study drug, you will enter a follow-up period. The study team will call you approximately every 3 months to see how you are feeling during this period.

Study Details

Full Title

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation

Principal Investigator

Harry
Erba

Protocol Number

PRO00109316

NCT ID

NCT04988555

Phase

I/II

Enrollment Status

Open to Enrollment